Low levels of NF1 expression were associated with primary and acquired resistance of lung adenocarcinomas to EGFR Thymidine Kinase Inhibitors in patients.

This study identifies a novel cohort of non-small cell lung cancer defined by NF1 mutation and suggests that ongoing therapeutic targeting strategies for KRAS tumors may also have efficacy in this population.

NF1 mutations define a unique molecular and clinicopathologic subtype of lung adenocarcinoma.

Results show that NF1 is highly expressed in non-small cell lung cancer (NSCLC) tissues and cell lines. In addition, H19 regulates NF1 expression through competitive binding to microRNA-107, thereafter participating in NSCLC development.

Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence.

Study found that 17.5% of lung adenocarcinoma were NF1 mutations and 8% were NF1 deletions. These NF1 alterations define a distinct clinical and molecular entity of lung adenocarcinoma.